PARP1 and cancer: Mechanistically, PARP1 inhibitors have been shown to compete with ligand NAD+, inhibit the PARylation of PARP1 or restoration by PARG enzyme resulting in increase in accumulation of DNA double-strand breaks (DSB) [26] leading to growth arrest/apoptosis in cancer cells.